Stockscreener 앱 받기
28.84
1.51%
0.43
시장 영업 전:
30.95
2.11
+7.32%
전일 마감가:
$28.41
열려 있는:
$28.45
하루 거래량:
321.39K
Relative Volume:
4.17
시가총액:
$1.28B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-3.35%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$26.68
$29.67
1주일 범위
$25.21
$29.80
52주 변동 폭
$25.05
$32.23
Avalyn Pharma Inc Stock (AVLN) Company Profile
Compare AVLN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
28.84 | 1.26B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Avalyn Pharma Inc 주식(AVLN)의 최신 뉴스
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Morgan Stanley initiates Avalyn Pharma stock coverage with overweight rating - Investing.com Australia
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs By Investing.com - Investing.com Australia
Jefferies initiates Avalyn Pharma stock with buy on lung disease data - Investing.com
Guggenheim initiates Avalyn Pharma stock with buy rating on fibrosis drugs - Investing.com Australia
Jefferies Initiates AVALYN PHARMA INC(AVLN.US) With Buy Rating, Announces Target Price $52 - Moomoo
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
AVLN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
AVLN News | AVALYN PHARMA INC (NASDAQ:AVLN) - ChartMill
Avalyn Pharma to present 4-year AP01 data at EULAR conference By Investing.com - Investing.com South Africa
Avalyn Pharma to present 4-year AP01 data at EULAR conference - Investing.com
4 years on inhaled pirfenidone for lung scarring at EULAR 2026 - Stock Titan
IPO Tracker 2026: Parabilis follows hefty Regeneron deal with IPO push - BioSpace
Top Avalyn Pharma (AVLN) Competitors 2026 - MarketBeat
AVLN SEC FilingsAVALYN PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Number of shareholders of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Avalyn Pharma prices $300M IPO at $18 per share - MSN
Suvretta funds build Avalyn Pharma (AVLN) stake via IPO and open-market buys - Stock Titan
SR One funds disclose 3.31M-share Avalyn Pharma (AVLN) position after IPO - Stock Titan
What is the current Price Target and Forecast for Avalyn Pharma Inc. (AVLN) - Zacks Investment Research
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma (AVLN) Stock Analysis Report | Financials & Insights - Benzinga
Perceptive group discloses 6.0% stake in Avalyn Pharma (NASDAQ: AVLN) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Avalyn brings patient feedback on lung fibrosis care to ATS 2026 - Stock Titan
Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference - The Manila Times
Lung disease drug developer Avalyn surges on public debut - MSN
Novo Holdings (NASDAQ: AVLN) buys shares and converts preferred into Avalyn common - Stock Titan
Avalyn Pharma Insider Bought Shares Worth $5,000,004, According to a Recent SEC Filing - Moomoo
Avalyn Pharma Inc. (AVLN) - Minichart
Preferred dividends of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
After tax other income/expense of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash per share of Avalyn Pharma Inc. – BOATS:AVLN - TradingView
Number of employees of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
AVLN PE Ratio & Valuation, Is AVLN Overvalued - Intellectia AI
Avalyn Pharma completes $345 million IPO on nasdaq - Investing.com India
AVLN Price Today: Avalyn Pharma Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Avalyn Pharma completes $345 million IPO on nasdaq By Investing.com - Investing.com Canada
Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026 - MarketBeat
IPO NewsUS IPO Weekly Recap: Biotech, early-stage mining, and Bill Ackman close out the April IPO market - renaissancecapital.com
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Avalyn Pharma closes $345 million IPO on Nasdaq By Investing.com - Investing.com Australia
Avalyn Pharma Inc. Completes Successful Initial Public Offering Raising $345 Million - Moomoo
Avalyn Pharma closes $345 million IPO on Nasdaq - Investing.com
Avalyn raises $345M as underwriters take all extra IPO shares - Stock Titan
Avalyn Announces Closing of Initial Public Offering and - GlobeNewswire
Avalyn Pharma Inc (AVLN) 재무 분석
Avalyn Pharma Inc (AVLN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Avalyn Pharma Inc 주식 (AVLN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Carroll Jill | Director |
May 01 '26 |
Buy |
18.00 |
277,778 |
5,000,004 |
2,186,562 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
May 01 '26 |
Buy |
18.00 |
555,555 |
9,999,990 |
2,186,562 |
2.98%
1.33%
자본화:
|
볼륨(24시간):